BioPharma Dive February 26, 2025
The financing is the second-largest this year involving one of the nearly two dozen venture firms tracked by BioPharma Dive.
Eikon Therapeutics, a well-funded drug startup run by Merck & Co.’s former research chief, has raised one of the biggest venture rounds for a biotechnology company so far this year.
The company on Wednesday announced nearly $351 million in Series D financing from more than a dozen investment firms, among them Lux Capital and Alexandria Venture Investments. The round is the second-largest in 2025 among the nearly two dozen venture firms tracked by BioPharma Dive. Eikon has now secured about $1.1 billion in venture dollars since its inception in 2019.
Eikon was formed around a Nobel Prize-winning technology that...
Today's Sponsors
Today's Sponsor